Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omnisart-AM
- Development stage
- Phase 4
- Lead developer
- Omnica Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Omnisart-AM is a branded generic fixed-dose combination medication developed and manufactured by Omnica Laboratories, a pharmaceutical company based in Nepal. It contains two antihypertensive agents: olmesartan medoxomil, an angiotensin II receptor blocker (ARB), and amlodipine besylate, a dihydropyridine calcium channel blocker (CCB). Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, which selectively blocks the binding of angiotensin II to the AT1 receptor in vascular smooth muscle, thereby inhibiting vasoconstriction. Amlodipine inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle cells, leading to peripheral vasodilation and reduced systemic vascular resistance. This combination is indicated for the treatment of hypertension, either as initial therapy or for patients not adequately controlled on single-agent therapy.
- Brand names
- Omnisart-AM
- Other names
- olmesartan medoxomil + amlodipine
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on Omnisart-AM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omnisart-AM.